Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00078754 · ClinicalTrials.gov registry record · Phase 2
A Comparison of Fluoxetine and Divalproex for the Treatment of Intermittent Explosive Disorder
A Phase 2 study of Intermittent Explosive Disorder, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT00078754 is a Phase 2 study of Intermittent Explosive Disorder that has completed, run by University of Chicago. The registered enrollment target is 90 participants, above the 76-participant average among 3 other Intermittent Explosive Disorder trials with a reported enrollment target (18% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00078754, a Phase 2 study of Intermittent Explosive Disorder, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will compare the medications fluoxetine (Prozac®) and divalproex (Depakote®) for the treatment of aggressive behavior in individuals with Intermittent Explosive Disorder (IED).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Fluoxetine
- DRUG Divalproex
Study Locations (1)
Illinois
- The University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2003-05 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00078754
The ClinicalTrials.gov registry entry for NCT00078754 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 76-participant average among 3 other Intermittent Explosive Disorder trials with a reported enrollment target (18% higher). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Intermittent Explosive Disorder appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00078754 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT00078754 about?
NCT00078754 is a clinical study titled "A Comparison of Fluoxetine and Divalproex for the Treatment of Intermittent Explosive Disorder". This study will compare the medications fluoxetine (Prozac®) and divalproex (Depakote®) for the treatment of aggressive behavior in individuals with Intermittent Explosive Disorder (IED).
What is the current status of trial NCT00078754?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2003-05. Estimated completion is 2008-10.
What conditions does trial NCT00078754 study?
This clinical trial studies the following conditions: Intermittent Explosive Disorder.
What interventions are being tested in trial NCT00078754?
The interventions under investigation include: Placebo (DRUG), Fluoxetine (DRUG), Divalproex (DRUG).
Who is sponsoring clinical trial NCT00078754?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00078754 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Intermittent Explosive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.